The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SK39 - interesting answer from you, thank you. Impressed by the way you are backing your industry knowledge and assessment of senior managers/owners. I wish I had your sector insight -it would give me more confidence in my own ability to evaluate TILS. Through my career I was always a generalist so never specialised in any particular areas. I do dabble in listed fund managers, however, given I worked for them for so long. I love their operational gearing and know all the different houses well.
It's reassuring to read that you are so convinced by the TILS portfolio. If the products are really so good then I guess we are down to execution risk given that we have the product quality and financial stability boxes ticked. I take great comfort in the fact these guys have done similar things before. They seem very credible.
Your deeper sector knowledge makes you much more of a conviction investor than me in TILS. I will be taking profits all the way up once this takes off again, no doubt leaving return on the table and missing out on the top, but ensuring I bag a good blended return.
And yes, the shorters are a pain but they are just smart investors taking advantage of a short-term opportunity. Eventually they will be squeezed out by the underlying value. They know it and will be ready to go soon enough.
I have no idea where the share price is ultimately heading ie how high it could go and when. However, we used to have a running joke on the last desk I worked on before retiring about stocks or funds we liked. If we thought something was really good we wouldn't try and call future price rises, we just used to say "it's going-up" and buy it. The thinking would be then be focused all around crystallising returns at sensible levels to lock-in our own performance.
TILS is "going-up".
Roker.. v good question. I work in pharma so I understand the relevance of mAB in practice. They are a growing market and huge income generators for a number of big pharma. I think GC mentioned 7 of the 10 biggest grossing drugs are mAB. There are a number of trials ongoing for covid-19 that focus on mAB as treatment options also. I think the patent on oral/nasal formulation is massive and that is the main reason for my investment. Everything else is a bonus. Stemprint is a very nice bonus. I didn't quite realise the relevance of it when I first invested but breast cancer is a huge market. I suspect there will be some big pharma interested in Accustem once we have done all the leg work and the CE mark and FDA approval are close. The covid play was a nice bonus too but i find it intriguing now as there is actually a realistic chance of success with immune modulators like foralumab. Look at article I posted yesterday and info posted on this board from clinical study in australia (am today). Now the value....
I think this company will get taken over for billions on the back of the trials for foralumab. I like the risk profile with the trial for Oral foralumab in crohns especially as that has shown efficacy (see research notes and previous trials using iv formulation of the drug in crohns). Based on the current portfolio I dont think I would be happy with with anything less then a 5 billion takeover. I like the bod and they have done it before. GC sold to bristol squibb for $2 billion a few years back. Covid has come at the right time for the company and has provided added opportunities. This stock for me is completely derisked because of the demerger (albeit with the inevitable reduction in sp post demerger). Hence I have built up a monster position. Nasdaq is disappointing but it will correct itself in time (as you keep telling me lol). I will derisk as we get closer to the trial results.
Finally I was just reading some of the stuff on the val board and it shows everything is a risk in life. Especially pharma. DYOR. Dont listen to rampers or derampers. Take responsibility for your own investing decisions and GLA.
Hi SK39
I've got quite a few of these now - many more than I would usually have a for a high vol single line like this....so what would you accept if a third party came in and made an offer for the whole of TILS tomorrow? I always ask myself this question when I have a worthwhile position - i.e. what would I take tomorrow for the risks I am facing today?
Raddy all i can say is that top up fund is well and truly empty. Only got 700 shares today and even that was at a push
Shiraz you must have a serious number of shares in here as you always seem to be buying. I wish I had your top up fund
they won't go under, they have over $50m in their Bank Account!
I think it's safe to say that TILS will reward you many times over!
I think its safe to say if tils goes under it will take me down with it
Bought some more at 140. Very small anounts now due to a severe lack of funds :(
Nasdaq spread is closer than ever. Great couple of months ahead coming.